Clinical trials: Intestinal Neoplasms
Colorectal Cancer, Nutritional Deficiency
PeRioperative Omega Three and the Effect on ImmuNity
Bowel cancer is the second most common cause of cancer-related death in the UK, with 50,000 new cases and over 15,000 deaths annually.
- Conditions
- Colorectal Cancer, Nutritional Deficiency, Infected Wound, Surgical Site Infection
- Trial name
- PROTEIN (NCT03598413)
- Testing
- Omega-3
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Metastatic Colorectal Cancer
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
- Trial name
- NCT02981524
- Testing
- CY, GVAX, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Cancer
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
The investigators planned a phase I study of preoperative CRT with capecitabine plus temozolomide inpatients with locally advanced resectable rectal cancer: 1) the role of temozolomide as a radiosensitizer has been well…
- Trial name
- NCT01781403
- Testing
- Temozolomide
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
Inflammatory Response in Laparoscopic and Open Colectomy
This study is designed to measure and compare the inflammatory response in laparoscopic and open colon cancer surgery
- Trial name
- NCT00942461
- Testing
- Laparoscopic colectomy, Open colectomy
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- G. Hatzikosta General Hospital
Colorectal Cancer
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
A randomized controlled study is conducted on patients with histological stage III colorectal cancer assigned to postoperative adjuvant therapy of uracil-tegafur plus leucovorin (UFT+LV), UFT+LV / UFT, or UFT+LV+PSK / UFT+PSK.
- Trial name
- NCT00209742
- Testing
- UFT, USEL/Leucovorin, Krestin
- Where
- Japan
- Volunteers
- 340 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
- Trial name
- NCT04429542
- Testing
- BCA101, Pembrolizumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Bicara Therapeutics
Colorectal Cancer
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients
1. Study Objectives 1) Primary Objective: Progression-free survival 2) Secondary Objectives: 1. overall survival 2. response rate 3. incidence, nature and severity of all adverse events 4. lipid lowering effect of simvastatin 5.
- Trial name
- NCT02026583
- Testing
- Simvastatin
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Samsung Medical Center
Anal Cancer
The Prevent Anal Cancer Palpation Study
Anal cancer is a common cancer among men having sex with men (MSM). We will investigate increasing detection of anal canal tumors through self- or partner-palpation of the anal canal among MSM and trans persons.
- Trial name
- NCT04090060
- Testing
- Practice Self-/Companion Exams, Control Arm
- Where
- 4 sites in United States
- Volunteers
- 718 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Gastric Cancer, Atrophic Gastritis
AG & IM in CA Stomach Protocol
This is a multi-center prospective case control study aiming to compare different methods of risk stratification models in predicting the risk of gastric cancer development.
- Conditions
- Gastric Cancer, Atrophic Gastritis, Intestinal Metaplasia
- Trial name
- NCT04184960
- Testing
- Gastroscopy and gastric biopsies
- Where
- 4 sites in Hong Kong, Japan and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with…
- Trial name
- NCT02688023
- Testing
- oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences
Stomach Neoplasms
Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
BVAC-B is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell. This study is Open-label, Accelerated titration, Multiple dosing study to evaluate the safety, tolerability, immune response and…
- Trial name
- BVAC-B (NCT03425773)
- Testing
- BVAC-B
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Cellid Co., Ltd.
Colorectal Cancer, Circulating Tumor Cell
Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC
Detecting circulating tumor cells from I-IV stage colorectal cancer patients pre-and post-operatively. Analyzing the morphology and biomarkers of CTCs and builting prognosis predicting model based on the morphology and biomarkers…
- Trial name
- NCT04912882
- Testing
- Circulating tumor cell
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Colorectal Cancer, Colorectal Liver Metastases
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or…
- Trial name
- IRIMAD (NCT06501482)
- Testing
- Postoperative reintroduction of FOLFIRI based chemotherapy
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastric Cancer
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction…
- Trial name
- NCT01824459
- Testing
- S-1, Oxaliplatin, Cisplatin
- Where
- China
- Volunteers
- 576 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Vulvar Cancer
CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas
The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer
- Trial name
- CaptHPV (NCT02981862)
- Testing
- CaptHPV method
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut de Cancérologie de Lorraine
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT05308446
- Testing
- Cetuximab, Encorafenib, Nivolumab
- Where
- 286 sites in United States, Puerto Rico
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
GENE EXPRESSION, Colorectal Cancer
Scottish Vitamin D Intervention Study
AIMS To identify the underlying mechanism by which Vitamin D reduces colorectal cancer risk. OBJECTIVES To demonstrate the effects of vitamin D supplementation on serum vitamin D levels.
- Trial name
- (SCoViDS) (NCT04868227)
- Testing
- FULTIUM D3 VITAMIN D3
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Colorectal Cancer
Diet and Physical Activity Program in Colorectal Cancer Survivor: a Randomized Controlled Trial
Colorectal cancers (CRC) represent the 1st digestive cancer and the 3rd cancer in the world. The World Cancer Research Fund summarized evidence from observational studies and concluded that low dietary fiber, and high red and…
- Trial name
- DPAP (NCT06194786)
- Testing
- Group D
- Where
- Tunisia
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Habib Bourguiba University Hospital
Colorectal Cancer
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897754
- Testing
- gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company